Literature DB >> 23620065

Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Mirja Wallner-Blazek1, Alex Rovira, Massimo Fillipp, Mara A Rocca, David H Miller, Klaus Schmierer, Jette Frederiksen, Achim Gass, Hugo Gama, Charles P Tilbery, Antonio J Rocha, José Flores, Frederik Barkhof, Alexandra Seewann, Jacqueline Palace, Tarek Yousry, Xavier Montalban, Christian Enzinger, Franz Fazekas.   

Abstract

Atypical lesions of a presumably idiopathic inflammatory demyelinating origin present quite variably and may pose diagnostic problems. The subsequent clinical course is also uncertain. We, therefore, wanted to clarify if atypical idiopathic inflammatory demyelinating lesions (AIIDLs) can be classified according to previously suggested radiologic characteristics and how this classification relates to prognosis. Searching the databases of eight tertiary referral centres we identified 90 adult patients (61 women, 29 men; mean age 34 years) with ≥ 1 AIIDL. We collected their demographic, clinical and magnetic resonance imaging data and obtained follow-up (FU) information on 77 of these patients over a mean duration of 4 years. The AIIDLs presented as a single lesion in 72 (80 %) patients and exhibited an infiltrative (n = 35), megacystic (n = 16), Baló (n = 10) or ring-like (n = 16) lesion appearance in 77 (86 %) patients. Additional multiple sclerosis (MS)-typical lesions existed in 48 (53 %) patients. During FU, a further clinical attack occurred rarely (23-35 % of patients) except for patients with ring-like AIIDLs (62 %). Further attacks were also significantly more often in patients with coexisting MS-typical lesions (41 vs. 10 %, p < 0.005). New AIIDLs developed in six (7 %), and new MS-typical lesions in 29 (42 %) patients. Our findings confirm the previously reported subtypes of AIIDLs. Most types confer a relatively low risk of further clinical attacks, except for ring-like lesions and the combination with MS-typical lesions.

Entities:  

Mesh:

Year:  2013        PMID: 23620065     DOI: 10.1007/s00415-013-6918-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  The nature of multiple sclerosis.

Authors:  Charles M Poser; Vesna V Brinar
Journal:  Clin Neurol Neurosurg       Date:  2004-06       Impact factor: 1.876

2.  T2 hypointense rims and ring-enhancing lesions in MS.

Authors:  Sara Llufriu; Teresa Pujol; Yolanda Blanco; Karolina Hankiewicz; Mattia Squarcia; Joan Berenguer; Pablo Villoslada; Francesc Graus; Albert Saiz
Journal:  Mult Scler       Date:  2010-08-04       Impact factor: 6.312

3.  Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese.

Authors:  Kun-Nan Zhang; Xiao-Mu Wu; Xu-Fang Xie; Xin-Hui Qu; Ying-Qiong Xiong
Journal:  Mult Scler       Date:  2008-01-21       Impact factor: 6.312

4.  Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.

Authors:  H S Malhotra; K K Jain; A Agarwal; M K Singh; S K Yadav; M Husain; N Krishnani; R K Gupta
Journal:  Mult Scler       Date:  2009-02       Impact factor: 6.312

5.  Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study.

Authors:  Julie Bolcaen; Marjan Acou; Koen Mertens; Giorgio Hallaert; Caroline Van den Broecke; Eric Achten; Ingeborg Goethals
Journal:  J Neuroimaging       Date:  2012-12-28       Impact factor: 2.486

6.  Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

Authors:  Takao Kiriyama; Hiroshi Kataoka; Toshiaki Taoka; Yasuyo Tonomura; Mari Terashima; Masami Morikawa; Emi Tanizawa; Makoto Kawahara; Yoshiko Furiya; Kazuma Sugie; Kimihiko Kichikawa; Satoshi Ueno
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

Review 7.  Acute disseminated encephalomyelitis.

Authors:  Silvia Tenembaum; Tanuja Chitnis; Jayne Ness; Jin S Hahn
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

8.  Conventional and advanced magnetic resonance imaging in tumefactive demyelination.

Authors:  Jitender Saini; Somenath Chatterjee; Bejoy Thomas; Chandrasekharan Kesavadas
Journal:  Acta Radiol       Date:  2011-10-24       Impact factor: 1.990

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

10.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

View more
  15 in total

Review 1.  Differential imaging of atypical demyelinating lesions of the central nervous system.

Authors:  Matteo Paoletti; Shaun Ivan Muzic; Francesca Marchetti; Lisa Maria Farina; Stefano Bastianello; Anna Pichiecchio
Journal:  Radiol Med       Date:  2021-01-24       Impact factor: 3.469

2.  Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Authors:  G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski
Journal:  J Neurol       Date:  2018-07-27       Impact factor: 4.849

3.  Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Authors:  Sherifa A Hamed
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

4.  Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.

Authors:  Mahboubeh Fereidan-Esfahani; Paul A Decker; Jeanette E Eckel Passow; Claudia F Lucchinetti; Eoin Patrick Flanagan; William Oliver Tobin
Journal:  Eur J Neurol       Date:  2021-12-09       Impact factor: 6.089

5.  Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.

Authors:  Masaki Kobayashi; Yuko Shimizu; Noriyuki Shibata; Shinichiro Uchiyama
Journal:  J Neurol       Date:  2014-07-18       Impact factor: 4.849

6.  Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.

Authors:  Matthew A Tremblay; Javier E Villanueva-Meyer; Soonmee Cha; Tarik Tihan; Jeffrey M Gelfand
Journal:  J Neurol Sci       Date:  2017-08-10       Impact factor: 3.181

Review 7.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

8.  Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis.

Authors:  Evan A Jolliffe; Yong Guo; Todd A Hardy; P Pearse Morris; Eoin P Flanagan; Claudia F Lucchinetti; W Oliver Tobin
Journal:  Neurology       Date:  2021-05-19       Impact factor: 11.800

9.  Balo's Concentric Sclerosis with Acute Presentation and Co-Existing Multiple Sclerosis-Typical Lesions on MRI.

Authors:  Bela Purohit; Eranga Ganewatte; Bettina Schreiner; Spyros Kollias
Journal:  Case Rep Neurol       Date:  2015-02-28

10.  A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome.

Authors:  Sharmilee Gnanapavan; Zane Jaunmuktane; Kelly Pegoretti Baruteau; Sakthivel Gnanasambandam; Klaus Schmierer
Journal:  BMC Neurol       Date:  2014-04-02       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.